Skip to main content

Advertisement

SpringerLink
Log in

Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma

  • Head and Neck
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The aim of this study was to evaluate the efficacy and the toxicity of paclitaxel and cisplatin in patients in concurrent radiotherapy for locally advanced nasopharyngeal carcinoma, and to see whether such a regime would be better tolerated than high dose cisplatin plus fluoracil in Chinese patients. Thirty-one patients with locally advanced nasopharyngeal carcinoma were enrolled. Patients were scheduled to receive two courses of concomitant chemotherapy, starting on day 1 and then day 28 during radiotherapy (70–76 Gy in 35–38 fractions in 7–7.5 weeks). Chemotherapy was given by intravenous infusion, paclitaxel 120 mg/m2 in 3 h, cisplatin 75 mg/m2 (25 mg/m2 days 1–3). Adjuvant therapy was paclitaxel 135 mg/m2 in 3 h, cisplatin 75 mg/m2 (25 mg/m2 days 1–3) on weeks 3, 6, 9 after radiotherapy. All patients completed radiotherapy, but for concomitant chemoradiotherapy, 20 of the 31 patients completed the 2 cycles of chemotherapy, while the other 11 could only receive 1 cycle due to various reasons. The median follow-up was 40 months, 2 patients developed locoregional recurrences, one of whom in the cervical lymph nodes, the other in the nasopharynx. The 3-year overall survival rate was 83.9% and the distant metastasis rate at 3 years was 13.6%. Grade 3–4 toxicities were neutropenia 12.9%, anaemia 6.45%, thrombocytopenia 3.22%, severe arrhythmia 3.2%, and hypersensitivity reaction 3.2%. In conclusion, paclitaxel with cisplatin as concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma is feasible, safe, and might improve regional control and survival rates in Chinese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Yi JL, Gao L, Huang XD et al (2006) Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys 65:161–168

    PubMed  Google Scholar 

  2. Gao JM, Zeng YX, Cui NJ et al (2005) Staging 915 cases of nasopharyngeal carcinoma after simple radical radiotherapy—checkout of Fuzhou staging system (1992). Ai Zheng 24:1165–1172

    Google Scholar 

  3. Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116

    PubMed  Google Scholar 

  4. He XY, Liu TF, He SQ et al (2007) Late course accelerated hyperfractionated radiotherapy of nasopharyngeal carcinoma (LCAF). Radiother Oncol 85:29–35

    Article  PubMed  Google Scholar 

  5. Zhu XD, Wei JB, Qu S et al (2007) Comparison of remote results of conventional fractionation radiotherapy and late course accelerated hyperfractionation radiotherapy for nasopharyngeal carcinoma. Chin J Radiat Oncol 16:321–324

    Google Scholar 

  6. Kwong DL, Sham JS, Au GK et al (2004) Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 22:2643–2653

    Article  CAS  PubMed  Google Scholar 

  7. Chua DT, Sham JS, Au GK (2004) A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. Head Neck 26:118–126

    Article  PubMed  Google Scholar 

  8. Jiang Y, Wei YQ, Luo F et al (2005) Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Invest 23:123–128

    PubMed  Google Scholar 

  9. Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317

    CAS  PubMed  Google Scholar 

  10. Lee AW, Lau WH, Tung SY et al (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966–6975

    Article  CAS  PubMed  Google Scholar 

  11. Mostafa E, Nasar MN, Rabie NA et al (2006) Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. J Egypt Natl Canc Inst 18:348–356

    PubMed  Google Scholar 

  12. Citrin D, Mansueti J, Likhacheva A et al (2009) Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 74:1040–1046

    PubMed  Google Scholar 

  13. Agarwala SS, Cano E, Heron DE et al (2007) Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol 18:1224–1229

    Article  CAS  PubMed  Google Scholar 

  14. Pignon JP, le Maitre A, Bourhis J (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69:S112–S114

    Google Scholar 

  15. Disilvestro PA, Walker JL, Morrison A et al (2006) Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol Oncol 103:1038–1042

    Article  CAS  PubMed  Google Scholar 

  16. Kao J, Conzen SD, jaskowiak NT et al (2005) Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 61:1045–1053

    CAS  PubMed  Google Scholar 

  17. Hsu FM, Lin CC, Lee JM et al (2008) Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. J Surg Oncol 98:34–41

    Article  PubMed  Google Scholar 

  18. Yap SP, Lim WT, Foo KF et al (2008) Induction concurrent chemoradiotherapy using Paclitaxel and Carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer—Asian experience. Ann Acad Med Singapore 37:377–382

    PubMed  Google Scholar 

  19. Langer CJ, Harris J, Horwitz EM et al (2007) Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 25:4800–4805

    Article  CAS  PubMed  Google Scholar 

  20. Fountzilas G, Tolis C, Kalogera-Fountzila A et al (2005) Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study. Med Oncol 22:269–279

    Article  CAS  PubMed  Google Scholar 

  21. Barone C, Grillo R, Dongiovanni D et al (2008) Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma. Anticancer Res 28:1285–1291

    CAS  PubMed  Google Scholar 

  22. Hancock SB, Krempl GA, Canfield V et al (2008) Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy. Laryngoscope 118:1357–1361

    Article  CAS  PubMed  Google Scholar 

  23. Hu QY, Liu P, Wang L et al (2007) Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III, IV a nasopharyngeal carcinoma. Ai zhen 26:394–397

    Google Scholar 

  24. Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589

    Article  CAS  PubMed  Google Scholar 

  25. Rades D, Fehlauer F, Sheikh-Sarraf M et al (2008) Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 30:235–241

    Article  PubMed  Google Scholar 

  26. Chan AT, Teo PML, Ngan RK et al (2002) Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III radiomized trial. J Clin Oncol 20:2038–2044

    Article  CAS  PubMed  Google Scholar 

  27. Demizu Y, Sasaki R, Soejima T et al (2006) Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma. Jpn J Clin Oncol 36:620–625

    Article  PubMed  Google Scholar 

  28. Vaupel P, Mayer A, Hockel M (2006) Impact Of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 182:63–71

    Article  PubMed  Google Scholar 

  29. Chau RM, Teo PM, Kam MK et al (2007) Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. Med Dosim 32:263–270

    Article  PubMed  Google Scholar 

  30. Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62:672–679

    PubMed  Google Scholar 

  31. Kong L, Zhang YW, Wu YR et al (2006) Late side reactions of longterm survivors after radiotherapy for nasopharyngeal carcinoma. Chin J Radiat Oncol 15:151–156

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Cancer Hospital, Fudan University, 399 Ling Ling Road, 200032, Shanghai, People’s Republic of China

    Xia-Yun He, Chao-Su Hu, Hong-Mei Ying, Yong-Ru Wu, Guo-Pei Zhu & Tai-Fu Liu

Authors
  1. Xia-Yun He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chao-Su Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-Mei Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong-Ru Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guo-Pei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tai-Fu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tai-Fu Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, XY., Hu, CS., Ying, HM. et al. Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 267, 773–778 (2010). https://doi.org/10.1007/s00405-009-1112-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-009-1112-7

Keywords

Search

Navigation